Logo image of NANO.PA

NANOBIOTIX (NANO.PA) Stock Fundamental Analysis

Europe - EPA:NANO - FR0011341205 - Common Stock

18.52 EUR
+1.52 (+8.94%)
Last: 10/6/2025, 7:00:00 PM
Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NANO. NANO was compared to 73 industry peers in the Biotechnology industry. NANO has a bad profitability rating. Also its financial health evaluation is rather negative. NANO does not seem to be growing, but still is valued expensively.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

NANO had negative earnings in the past year.
NANO had a negative operating cash flow in the past year.
NANO had negative earnings in each of the past 5 years.
In the past 5 years NANO always reported negative operating cash flow.
NANO.PA Yearly Net Income VS EBIT VS OCF VS FCFNANO.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 -20M -40M -60M

1.2 Ratios

Looking at the Return On Assets, with a value of -101.06%, NANO is doing worse than 71.23% of the companies in the same industry.
Industry RankSector Rank
ROA -101.06%
ROE N/A
ROIC N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NANO.PA Yearly ROA, ROE, ROICNANO.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1K 2K

1.3 Margins

NANO does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NANO.PA Yearly Profit, Operating, Gross MarginsNANO.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 -100K -200K -300K -400K -500K

More info and screens

1

2. Health

2.1 Basic Checks

NANO does not have a ROIC to compare to the WACC, probably because it is not profitable.
NANO has more shares outstanding than it did 1 year ago.
Compared to 5 years ago, NANO has more shares outstanding
NANO has a worse debt/assets ratio than last year.
NANO.PA Yearly Shares OutstandingNANO.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 10M 20M 30M 40M
NANO.PA Yearly Total Debt VS Total AssetsNANO.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

2.2 Solvency

NANO has an Altman-Z score of -7.68. This is a bad value and indicates that NANO is not financially healthy and even has some risk of bankruptcy.
NANO has a Altman-Z score of -7.68. This is in the lower half of the industry: NANO underperforms 72.60% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -7.68
ROIC/WACCN/A
WACC7.72%
NANO.PA Yearly LT Debt VS Equity VS FCFNANO.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 20M -20M 40M -40M 60M -60M

2.3 Liquidity

A Current Ratio of 1.04 indicates that NANO should not have too much problems paying its short term obligations.
Looking at the Current ratio, with a value of 1.04, NANO is doing worse than 71.23% of the companies in the same industry.
NANO has a Quick Ratio of 1.04. This is a normal value and indicates that NANO is financially healthy and should not expect problems in meeting its short term obligations.
Looking at the Quick ratio, with a value of 1.04, NANO is doing worse than 67.12% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.04
Quick Ratio 1.04
NANO.PA Yearly Current Assets VS Current LiabilitesNANO.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M

More info and screens

3

3. Growth

3.1 Past

The earnings per share for NANO have decreased strongly by -33.33% in the last year.
NANO shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -138.62%.
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
Revenue 1Y (TTM)-138.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-150.07%

3.2 Future

The Earnings Per Share is expected to grow by 26.98% on average over the next years. This is a very strong growth
NANO is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 37.57% yearly.
EPS Next Y48.11%
EPS Next 2Y34.49%
EPS Next 3Y28.66%
EPS Next 5Y26.98%
Revenue Next Year70.64%
Revenue Next 2Y91.53%
Revenue Next 3Y60.31%
Revenue Next 5Y37.57%

3.3 Evolution

NANO.PA Yearly Revenue VS EstimatesNANO.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 100M 200M 300M 400M 500M
NANO.PA Yearly EPS VS EstimatesNANO.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2016 2018 2020 2022 2024 2026 2028 2030 2032 0 1 -1 2 -2

More info and screens

1

4. Valuation

4.1 Price/Earnings Ratio

NANO reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Also next year NANO is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NANO.PA Price Earnings VS Forward Price EarningsNANO.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 -20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NANO.PA Per share dataNANO.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -0.5 -1

4.3 Compensation for Growth

NANO's earnings are expected to grow with 28.66% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y34.49%
EPS Next 3Y28.66%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NANO!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

NANOBIOTIX

EPA:NANO (10/6/2025, 7:00:00 PM)

18.52

+1.52 (+8.94%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)09-30 2025-09-30
Earnings (Next)11-10 2025-11-10
Inst Owners26.36%
Inst Owner ChangeN/A
Ins Owners0.63%
Ins Owner ChangeN/A
Market Cap892.94M
Analysts86.67
Price Target11.92 (-35.64%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)4.47%
PT rev (3m)4.47%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)11.53%
EPS NY rev (3m)22.24%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)61.26%
Revenue NY rev (3m)76.5%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-1.44
EYN/A
EPS(NY)-0.75
Fwd EYN/A
FCF(TTM)-0.42
FCFYN/A
OCF(TTM)-0.41
OCFYN/A
SpS-0.24
BVpS-1.36
TBVpS-1.36
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -101.06%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-79.59%
ROA(5y)-62%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score2
Asset Turnover-0.17
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 52.31%
Cap/Sales -7.3%
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 1.04
Quick Ratio 1.04
Altman-Z -7.68
F-Score2
WACC7.72%
ROIC/WACCN/A
Cap/Depr(3y)26.93%
Cap/Depr(5y)20.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)-33.33%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-250%
EPS Next Y48.11%
EPS Next 2Y34.49%
EPS Next 3Y28.66%
EPS Next 5Y26.98%
Revenue 1Y (TTM)-138.62%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%-150.07%
Revenue Next Year70.64%
Revenue Next 2Y91.53%
Revenue Next 3Y60.31%
Revenue Next 5Y37.57%
EBIT growth 1Y-155.39%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year2.1%
EBIT Next 3Y37.5%
EBIT Next 5Y36.1%
FCF growth 1Y-59.21%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-56.71%
OCF growth 3YN/A
OCF growth 5YN/A